Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Axsome Therapeutics (NASDAQ:AXSM) issued its quarterly earnings results on Monday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.14, Briefing.com reports. The business had revenue of $196.00 million during the quarter, compared to analysts’ expectations of $191.33 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The company’s revenue was up 65.0% on a year-over-year basis.

Here are the key takeaways from Axsome Therapeutics’ conference call:

• Axsome reported strong commercial momentum with Q4 product revenue of $196 million and full-year revenue of $638.5 million, driven by Auvelity surpassing $507.1 million in annual sales and continued prescription growth.
• The company announced acceptance and Priority Review of the sNDA for VIVALITY in Alzheimer’s disease agitation with a PDUFA action date of April 30, and is executing launch readiness including a planned salesforce expansion as a near‑term potential catalyst.
• Pipeline progress is broad — imminent NDA submission for AXS-12 in narcolepsy, multiple Phase 3 programs for solriamfetol (ADHD pediatric, MDD with EDS, binge eating with top-line expected H2 2026, shift work disorder in 2027), initiation of AXS-14 Phase 3 in fibromyalgia, and acquisition of AZD7325 (AXS-17) advancing toward Phase 2 in epilepsy.
• Axsome narrowed its full-year net loss to $183.2 million, ended 2025 with $323 million in cash, and states that cash is sufficient to fund operations into cash-flow positivity — a forward-looking claim that depends on execution and market dynamics.
• Commercial margins face pressure as Auvelity and Sunosi gross-to-net discounts were in the high‑40% range and are expected to rise to the mid‑50% range (Q1 dynamics), Symbravo GTN is ~high‑70% during launch, and SG&A rose 39% to $570.6 million amid a planned salesforce increase to ~600 reps, all of which may weigh on near-term profitability.

Axsome Therapeutics Trading Down 2.5%

Shares of Axsome Therapeutics stock traded down $4.54 on Monday, reaching $179.19. The company had a trading volume of 131,792 shares, compared to its average volume of 651,847. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The firm has a market cap of $9.03 billion, a PE ratio of -38.67, a PEG ratio of 13.22 and a beta of 0.40. The firm’s 50 day moving average price is $173.88 and its two-hundred day moving average price is $144.44. Axsome Therapeutics has a 52-week low of $86.99 and a 52-week high of $191.50.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 78,703 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $171.28, for a total value of $13,480,249.84. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,238,183.12. The trade was a 91.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total value of $1,383,300.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 308,874 shares of company stock valued at $51,390,805. Corporate insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in shares of Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after acquiring an additional 609,516 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock worth $275,763,000 after buying an additional 472,422 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Axsome Therapeutics by 73.3% in the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after buying an additional 419,008 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Axsome Therapeutics by 831.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock valued at $46,662,000 after buying an additional 399,000 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Axsome Therapeutics by 566.5% during the third quarter. Marshall Wace LLP now owns 378,024 shares of the company’s stock worth $45,911,000 after acquiring an additional 321,308 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 target price on shares of Axsome Therapeutics in a report on Monday. Wells Fargo & Company upped their target price on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. HC Wainwright lifted their price target on Axsome Therapeutics from $200.00 to $260.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Finally, Mizuho set a $230.00 price target on shares of Axsome Therapeutics in a report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $216.07.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.